PTC Therapeutics (PTCT) has disclosed a new risk, in the Regulation category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PTC Therapeutics faces a significant business risk as outlined in their Annual Report on Form 10-K for the year ended December 31, 202. This risk could potentially impact their operational capabilities and financial performance. Stakeholders should closely monitor how the company addresses these challenges to mitigate potential negative outcomes. The company’s ability to navigate this risk will be crucial for its future stability and growth.
The average PTCT stock price target is $68.86, implying 35.18% upside potential.
To learn more about PTC Therapeutics’ risk factors, click here.